- Fisher & Paykel delivered an operating revenue of $900 million in H1 FY22, down 1% on pcp.
- The Group has 2 product groups - the Hospital and the Homecare product group.
- FPH produced 36% of its revenue from North America and 30% from the Asia Pacific region in H1 FY22.
The Group’s products are structured in two parts, namely the Hospital and the Homecare group.
Image source: © 2021 Kalkine Media®, Data source- Refinitiv
The Hospital product group involves products used in invasive ventilation, non-invasive ventilation, nasal high-flow therapy, and laparoscopic and open surgery.
These products not only help healthcare providers in enhancing patient results but also provide economic benefits by reducing the need to increase care and patient stays in hospital.
The other product group is homecare that includes devices and systems used to cure obstructive sleep apnea (OSA) and offer respiratory support at homes. These consist of FPH’s CPAP therapy masks and flow creators, data management tools and interfaces.
FPH’s performance across products group
FPH’s first half of FY22 has continued to be strong with the Group delivering an operating revenue of $900 million for the period. The Group witnessed increased demand for most of its hospital products amid a surge in COVID-19 cases globally.
While the hospital product group accounted for 74% of FPH’s operating revenue, the homecare product group generated 25% of the Group’s revenue for the 6 months ended 30 September 2021. Hospital hardware sales dropped 10% for the first half while sales for hospital consumables rose 24% on pcp in constant currency.
FPH generated an operating revenue of $670.2 million and $226.9 million from the hospital product group and the Homecare product group, respectively, in 1HFY22.
FPH’s largest markets by revenue are North America, Europe and the Asia Pacific.
Fisher generated 36% of its revenue from North America, 26% from Europe, 30% from the Asia Pacific and 8% from other global markets for the 6 months ended 30 September 2021.
FPH also launched the Visairo mask for non-invasive ventilation in the US in August. The Group also launched the Evora Full mask for OSA in NZ and Australia in October.
Shares of Fisher & Paykel gained 0.46% in trading on Wednesday to close at $33.
Fisher plans to invest nearly $700 million over the next 5 years to maintain its extra manufacturing and distribution capacity to scale up faster.
(NOTE: Currency is reported in NZ Dollar unless stated otherwise)